NEW YORK--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on March 2, 2020, the Company granted a newly hired, non-executive employee a non-statutory stock option to purchase 18,500 shares of the Company’s common stock. In addition, on March 2, 2020, the Company granted this employee a grant of 9,250 restricted stock units for shares of the Company’s common stock. These grants were made pursuant to the Company’s 2019 Inducement Stock Incentive Plan, were approved by the Company’s compensation committee pursuant to a delegation by the Company’s board of directors, and were made as a material inducement to this employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The stock option has an exercise price of $5.61 per share, equal to the closing price of IVERIC bio’s common stock on March 2, 2020. The stock option has a ten year term and vests over four years, with 25% of the shares underlying the option vesting on March 2, 2021 and an additional 2.0833% of the shares underlying the option vesting at the end of each successive month thereafter. The restricted stock unit grant vests with respect to 25% of the shares underlying the grant on each of March 2, 2021, March 2, 2022, March 2, 2023 and March 2, 2024. The vesting of each grant is subject to the employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.

About IVERIC bio

IVERIC bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. Vision is Our Mission. For more information on the Company please visit www.ivericbio.com.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005245/en/

Investor Contact:
IVERIC bio
Kathy Galante, 212-845-8231
Vice President, Investor Relations and Corporate Communications
kathy.galante@ivericbio.com

or

Media Contact:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Source: IVERIC bio, Inc.